Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

ABSTRACT

Compositions and methods for treating glaucoma are provided. In particular hydrophilic ester prodrugs and their use to reduce central corneal thickening is provided.

RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No.13/974,975, filed Aug. 23, 2013, which claims the benefit of U.S.Provisional Patent Application Ser. No. 61/693,437, filed Aug. 27, 2012,the disclosures of which are hereby incorporated in their entiretyherein by reference.

BACKGROUND OF THE INVENTION

Glaucoma is one of the leading causes of blindness in the world, withover 2.5 million people in the United States suffering from the diseaseand several million more being at risk of developing glaucoma. As thepopulation ages, the number of individuals suffering from glaucoma willcontinue to grow since the elderly are being affected disproportionally.

Based on its etiology, glaucoma can be classified into primary andsecondary glaucoma. Primary glaucoma, also known as congenital glaucoma,can occur in the absence of other ocular conditions and its underlyingcauses are not known. However, it is known that increased intraocularpressure (TOP) observed in primary glaucoma is due to the obstruction ofaqueous humor flow out of the eye. Secondary glaucoma results fromanother pre-existing ocular disease such as, uveitis, an intraoculartumor, enlarged cataract, central retinal vein occlusion, trauma to theeye, operative procedures and intraocular hemorrhage. Generally, anyinterference with the outward flow of aqueous humor from the posteriorchamber into the anterior chamber and subsequently, into the canal ofSchlemm can lead to secondary glaucoma.

Current treatments for glaucoma aim to reduce the pressure in the eye bydecreasing the amount of aqueous fluid being produced or alternativelyby enhancing the flow of fluid out of the eye by using mechanical means.Agents for topical application used to treat glaucoma include miotics(e.g. Isopto® Carpine, Ocusert®, Pilocar®, and Pilopine®) andepinephrines (e.g. Epifrin® and Propine®), which increase the outflow offluid; beta blockers (e.g. Betagan®, Betimol®, Betoptic®, Ocupress®,Timoptic®, Optipranalol®), carbonic anhydrase inhibitors and alphaandrenergic agonists (e.g. Alphagan®, Iopidine®, Trusopt®), which reducethe amount of fluid; and prostaglandin analogs (e.g. Lumigan®, Rescula®,Travatan®, Xalatan®), which increase the outflow of fluid through asecondary drainage route.

The topical application of ophthalmic compositions for the treatment ofglaucoma requires penetration of the drug through the cornea and intothe anterior chamber, which contains aqueous humor, which then drainsinto the conventional outflow pathway. Intraoccular pressure is loweredby drugs acting in the Schlemm's canal and the uveal-scleral pathway.Penetration of the drug through the cornea requires a balance ofhydrophobic and hydrophilic characteristics. In order to diffuse intothe cornea the drug must be sufficiently soluble in non-polar media andit must be sufficiently soluble in aqueous media in order to diffuse outof the cornea into the aqueous humor.

Potentially useful drugs for the treatment of glaucoma can be deliveredas prodrug esters. The use of prodrug esters, which are cleavedenzymatically (e.g. in the cornea) to regenerate the active compound,can enhance penetration of the drug through the cornea into the anteriorchamber. However, many esters are too hydrophobic to diffuse out of thehighly aqueous polar stroma, the thickest layer, in the cornea and intothe aqueous humor. Further, such compounds are often not sufficientlysoluble to formulate in aqueous solutions. There is a need in the artfor ophthalmic compositions having the capability to penetrate throughthe cornea into the anterior chamber. At the same time such compositionsneed to exhibit sufficient hydrophilic properties to formulate inaqueous solution and to be soluble in the anterior chamber. Providedherein are compositions and methods addressing these and other needs inthe art.

BRIEF SUMMARY OF THE INVENTION

In one aspect, a compound having the formula

or pharmaceutically acceptable salt thereof is provided. In formula (I)R¹ is substituted or unsubstituted aryl or substituted or unsubstitutedheteroaryl. L¹ is a bond, substituted or unsubstituted C₁-C₁₀ alkyleneor substituted or unsubstituted 2 to 10 membered heteroalkylene. L² is abond, substituted or unsubstituted C₁-C₁₀ alkylene, substituted orunsubstituted arylene or substituted or unsubstituted heteroarylene. L³is a bond or substituted or unsubstituted C₁-C₁₀ alkylene. R² issubstituted or unsubstituted alkyl, substituted or unsubstitutedheteroalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl.

In another aspect, an ophthalmic pharmaceutical composition includingthe compound provided herein and embodiments thereof and apharmaceutically acceptable carrier is provided.

In another aspect, a method of treating an ophthalmic disease in a humanis provided. The method includes administering a therapeuticallyeffective amount of the compound provided herein and embodiments thereofto a subject in need thereof.

In another aspect, a method of reducing corneal thickening is provided.The method includes administering a therapeutically effective amount ofthe compound provided herein and embodiments thereof to a subject inneed thereof.

DETAILED DESCRIPTION OF THE INVENTION I. Definitions

The abbreviations used herein have their conventional meaning within thechemical and biological arts. The chemical structures and formulae setforth herein are constructed according to the standard rules of chemicalvalency known in the chemical arts.

Where substituent groups are specified by their conventional chemicalformulae, written from left to right, they equally encompass thechemically identical substituents that would result from writing thestructure from right to left, e.g., —CH₂O— is equivalent to —OCH₂—.

The term “alkyl,” by itself or as part of another substituent, means,unless otherwise stated, a straight (i.e. unbranched) or branched chain,or combination thereof, which may be fully saturated (referred to hereinas a “saturated alkyl”), mono- or polyunsaturated and can include di-and multivalent radicals, having the number of carbon atoms designated(i.e. C₁-C₁₀ means one to ten carbons). In some embodiments, all alkylsset forth as a substituent of the compounds provided herein aresaturated alkyls. Examples of saturated hydrocarbon radicals include,but are not limited to, groups such as methyl, ethyl, n-propyl,isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, homologs and isomersof, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. Anunsaturated alkyl group is one having one or more double bonds or triplebonds. An “alkoxy” is an alkyl attached to the remainder of the moleculevia an oxygen linker (—O—). An “alkylthio” is an alkyl attached to theremainder of the molecule via an sulfur linker (—S—). A “haloalkoxy” isan alkoxy substituted with a halogen. When the halogen is a fluoro, itis referred to herein as a “fluoroalkoxy.” The term “alkyl” includessaturated alkyl, alkenyl and alkynyl. A saturated alkyl may have from 1to 10 or 1 to 6 carbon atoms. The term “alkenyl” by itself or as part ofanother substituent, means, unless otherwise stated, a straight (i.e.unbranched) or branched hydrocarbon chain (e.g., two to ten, or two tosix carbon atoms) having one or more double bonds. Examples ofunsaturated alkyl groups include, but are not limited to, vinyl,2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl,3-(1,4-pentadienyl), and the like. The term “alkynyl” by itself or aspart of another substituent, means, unless otherwise stated, a straight(i.e. unbranched) or branched hydrocarbon chain (e.g., two to ten or twoto six carbon atoms) having one or more triple bonds. Examples ofalkynyl groups include, but are not limited to, ethynyl, 1- and3-propynyl, 3-butynyl, and the like.

The term “alkylene”, “alkenylene, and “alkynylene” by itself or as partof another substituent means a divalent radical derived from an alkyl,alkenyl, or alkynyl as exemplified, but not limited, by methylene,ethylene, —CH₂CH₂CH₂CH₂—, vinylene and the like.

The term “amino” as used herein means a —NH₂. The term “carboxy” as usedherein means —COOH (including pharmaceutically acceptable saltsthereof).

The term “heteroalkyl,” by itself or in combination with another term,means, unless otherwise stated, a stable straight or branched chain orcombinations thereof, consisting of at least one carbon atom and atleast one heteroatom selected from the group consisting of O, N, P, Sior S, and wherein the nitrogen and sulfur atoms may optionally beoxidized and the nitrogen heteroatom may optionally be quaternized. Theheteroatom(s) O, N, P and S and Si may be placed at any interiorposition of the heteroalkyl group or at the position at which the alkylgroup is attached to the remainder of the molecule. Examples include,but are not limited to, —CH₂—CH₂—O—CH₃, —CH₂—CH₂—NH—CH₃,—CH₂—CH₂—N(CH₃)—CH₃, —CH₂—S—CH₂—CH₃, —CH₂—CH₂, —S(O)—CH₃,—CH₂—CH₂—S(O)₂—CH₃, —CH═CH—O—CH₃, —Si(CH₃)₃, —CH₂—CH═N—OCH₃,—CH═CH—N(CH₃)—CH₃, —O—CH₃, —O—CH₂—CH₃, and —CN. Up to two heteroatomsmay be consecutive, such as, for example, —CH₂—NH—OCH₃. Similarly, theterm “heteroalkylene” by itself or as part of another substituent meansa divalent radical derived from heteroalkyl, as exemplified, but notlimited by, —CH₂—CH₂—S—CH₂—CH₂— and —CH₂—S—CH₂—CH₂—NH—CH₂—. Forheteroalkylene groups, heteroatoms can also occupy either or both of thechain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino,alkylenediamino, and the like). As described above, heteroalkyl groups,as used herein, include those groups that are attached to the remainderof the molecule through a heteroatom

The terms “cycloalkyl” and “heterocycloalkyl,” by themselves or incombination with other terms, represent, unless otherwise stated,non-aromatic cyclic versions of “alkyl” and “heteroalkyl”, respectively(e.g., having 4 to 8 ring atoms). Additionally, for heterocycloalkyl, aheteroatom can occupy the position at which the heterocycle is attachedto the remainder of the molecule. Heterocycloalkyls may include one ortwo ring heteroatoms selected from N, O, or S(O)_(n′), where n′ is aninteger from 0 to 2, the remaining ring atoms being carbon. Theheterocycloalkyl or cycloalkyl ring is optionally fused to one or morearyl or heteroaryl rings as defined herein (e.g., where the aryl andheteroaryl rings are monocyclic). The heterocycloalkyl or cycloalkylring fused to monocyclic aryl or heteroaryl ring may be referred to inthis Application as “bicyclic heterocycloalkyl” ring or a “bicycliccycloalkyl” ring. Additionally, one or two ring carbon atoms in theheterocycloalkyl ring can optionally be replaced by a —CO— group. Morespecifically the term heterocycloalkyl includes, but is not limited to,pyrrolidino, piperidino, homopiperidino, 2-oxopyrrolidinyl,2-oxopiperidinyl, morpholino, piperazino, tetrahydropyranyl,thiomorpholino, dihydroindolyl, and the like. When the heterocycloalkylring is unsaturated it can contain one or two ring double bonds providedthat the ring is not aromatic. When the heterocycloalkyl group containsat least one nitrogen atom, it may also be referred to herein asheterocycloamino and is a subset of the heterocycloalkyl group. When theheterocycloalkyl group is a saturated ring and is not fused to aryl orheteroaryl ring as stated above, it may be referred to herein as asaturated monocyclic heterocycloalkyl. Examples of cycloalkyl include,but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.Examples of heterocycloalkyl include, but are not limited to,1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl,3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl,tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl,1-piperazinyl, 2-piperazinyl, and the like. A “cycloalkylene” and a“heterocycloalkylene,” alone or as part of another substituent means adivalent radical derived from a cycloalkyl and heterocycloalkyl,respectively.

The terms “halo” or “halogen,” by themselves or as part of anothersubstituent, mean, unless otherwise stated, a fluorine, chlorine,bromine, or iodine atom. Additionally, terms such as “haloalkyl,” aremeant to include monohaloalkyl and polyhaloalkyl. For example, the term“halo(C₁-C₄)alkyl” is meant to include, but not be limited to,fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl,4-chlorobutyl, 3-bromopropyl, and the like.

The term “acyl” means —C(O)R where R is a substituted or unsubstitutedalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted heteroalkyl, substituted or unsubstitutedheterocycloalkyl, substituted or unsubstituted aryl or substituted orunsubstituted heteroaryl.

The term “aryl” means, unless otherwise stated, an aromatic substituentwhich can be a single ring or multiple rings (preferably from 1 to 3rings) which may be fused together (i.e. a fused ring aryl) or linkedcovalently. A fused ring aryl refers to multiple rings fused togetherwherein at least one of the fused rings is an aryl ring (e.g., phenyl,1-naphthyl, 2-naphthyl, or 4-biphenyl). The term “heteroaryl” refers toaryl groups (or rings) that contain one or more (e.g., 4) heteroatomsselected from N, O, and S, wherein the nitrogen and sulfur atoms areoptionally oxidized, and the nitrogen atom(s) are optionallyquaternized, the remaining ring atoms being carbon. The heteroaryl maybe a monovalent monocyclic, bicyclic, or tricyclic (e.g., monocyclic orbicyclic) aromatic radical of 5 to 14 (e.g., 5 to 10) ring atoms whereone or more, (e.g., one, two, or three or four) ring atoms areheteroatom selected from N, O, or S. Examples include, but are notlimited to, thienyl, isoindolyl, benzoxazolyl, pyridazinyl, triazolyl,tetrazolyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl,2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl,5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl,4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl,2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl,5-benzothiazolyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl,5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and6-quinolyl. Thus, the term “heteroaryl” includes fused ring heteroarylgroups (i.e. multiple rings fused together wherein at least one of thefused rings is a heteroaromatic ring). A 5,6-fused ring heteroarylrefers to two rings fused together, wherein one ring has 5 members andthe other ring has 6 members, and wherein at least one ring is aheteroaryl ring. Likewise, a 6,6-fused ring heteroaryl refers to tworings fused together, wherein one ring has 6 members and the other ringhas 6 members, and wherein at least one ring is a heteroaryl ring. And a6,5-fused ring heteroaryl refers to two rings fused together, whereinone ring has 6 members and the other ring has 5 members, and wherein atleast one ring is a heteroaryl ring. A heteroaryl group can be attachedto the remainder of the molecule through a carbon or heteroatom. An“arylene” and a “heteroarylene,” alone or as part of another substituentmeans a divalent radical derived from an aryl and heteroaryl,respectively.

The terms “arylalkyl” and “heteroarylalkyl” is meant to include thoseradicals in which an aryl group or a heteroaryl group is attached to analkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like)including those alkyl groups in which a carbon atom (e.g., a methylenegroup) has been replaced by, for example, an oxygen atom (e.g.,phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxyl)propyl, and thelike).

The term “oxo” as used herein means an oxygen that is double bonded to acarbon atom. The term “carbonyl” as used herein refers to a —C(O)—group.

The symbol “

” indicates, as customary in the art, the point of attachment of asubstituent.

“Optional” or “optionally” means that the subsequently described eventor circumstance may but need not occur, and that the descriptionincludes instances where the event or circumstance occurs and instancesin which it does not. For example, “heterocycloalkyl group optionallysubstituted with an alkyl group” means that the alkyl may but need notbe present, and the description includes situations where theheterocycloalkyl group is substituted with an alkyl group and situationswhere the heterocycloalkyl group is not substituted with alkyl.

The term “alkylsulfonyl” as used herein means a moiety having theformula —S(O₂)—R′, where R′ is an alkyl group as defined above. R′ mayhave a specified number of carbons (e.g., “C₁-C₄ alkylsulfonyl”).

Each of the above terms (e.g., “alkyl,” “heteroalkyl,” “aryl” and“heteroaryl”) are meant to include both substituted and unsubstitutedforms of the indicated radical unless stated otherwise.

Substituents for the alkyl and heteroalkyl radicals (including thosegroups often referred to as alkylene, alkenyl, heteroalkylene,heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, andheterocycloalkenyl) can be one or more of a variety of groups selectedfrom, but not limited to: —OR′, ═O, ═NR′, ═N—OR′, —NR′R″, —SR′,-halogen, —SiR′R″R′″, —OC(O)R′, —C(O)R′, —CO₂R′, —CONR′R″, —OC(O)NR′R″,—NR″C(O)R′, —NR′—C(O)NR″R′″, —NR″C(O)₂R′, —NR′—C(NR′R″R′″)═NR″″,—NR—C(NR′ R″)═NR″, —S(O)R′, —S(O)₂R′, —S(O)₂NR′R″, —NRSO₂R′, —CN and—NO₂ in a number ranging from zero to (2m′+1), where m′ is the totalnumber of carbon atoms in such radical. R′, R″, R′″ and R″ eachindependently refer to hydrogen, substituted or unsubstitutedheteroalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g.,aryl substituted with 1-3 halogens), substituted or unsubstituted alkyl,alkoxy or thioalkoxy groups, or arylalkyl groups. When a compound of theinvention includes more than one R group, for example, each of the Rgroups is independently selected as are each R′, R″, R′″ and R″″ groupswhen more than one of these groups is present. When R′ and R″ areattached to the same nitrogen atom, they can be combined with thenitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example,—NR′R″ is meant to include, but not be limited to, 1-pyrrolidinyl and4-morpholinyl. From the above discussion of substituents, one of skillin the art will understand that the term “alkyl” is meant to includegroups including carbon atoms bound to groups other than hydrogengroups, such as haloalkyl (e.g., —CF₃ and —CH₂CF₃) and acyl (e.g.,—C(O)CH₃, —C(O)CF₃, —C(O)CH₂OCH₃, and the like).

Similar to the substituents described for the alkyl radical,substituents for the aryl and heteroaryl groups are varied and may beselected from, for example: halogen, —OR′, —NR′R″, —SR′, -halogen,—SiR′R″R′″, —OC(O)R′, —C(O)R′, —CO₂R′, —CONR′R″, —OC(O)NR′R″,—NR″C(O)R′, —NR′—C(O)NR′R″, —NR″C(O)₂R′, —NR—C(NR′R″R′″)═NR′″,—NR′—C(NR′R″)═NR′″, —S(O)R′, —S(O)₂R′, —S(O)₂NR′R″, —NR′SO₂R′, —CN and—NO₂, —R′, —N₃, —CH(Ph)₂, fluoro(C₁-C₄)alkoxy, and fluoro(C₁-C₄)alkyl,in a number ranging from zero to the total number of open valences onthe aromatic ring system; and where R′, R″, R′″ and R″″ are preferablyindependently selected from hydrogen, substituted or unsubstitutedalkyl, substituted or unsubstituted heteroalkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,substituted or unsubstituted aryl and substituted or unsubstitutedheteroaryl. When a compound of the invention includes more than one Rgroup, for example, each of the R groups is independently selected asare each R′, R″, R′″ and R″″ groups when more than one of these groupsis present.

Two of the substituents on adjacent atoms of the aryl or heteroaryl ringmay optionally form a ring of the formula -T-C(O)—(CRR′)_(q)—U—, whereinT and U are independently —NR—, —O—, —CRR′— or a single bond, and q isan integer of from 0 to 3. Alternatively, two of the substituents onadjacent atoms of the aryl or heteroaryl ring may optionally be replacedwith a substituent of the formula -A-(CH₂)_(r)—B—, wherein A and B areindependently —CRR′—, —O—, —NR—, —S—, —S(O)—, —S(O)₂—, —S(O)₂NR′— or asingle bond, and r is an integer of from 1 to 4. One of the single bondsof the new ring so formed may optionally be replaced with a double bond.Alternatively, two of the substituents on adjacent atoms of the aryl orheteroaryl ring may optionally be replaced with a substituent of theformula —(CRR′)_(s)—X′—(C″R′″)_(d)—, where s and d are independentlyintegers of from 0 to 3, and X′ is —O—, —NR′—, —S—, —S(O)—, —S(O)₂—, or—S(O)₂NR′—. The substituents R, R′, R″ and R′″ are preferablyindependently selected from hydrogen, substituted or unsubstitutedalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl, andsubstituted or unsubstituted heteroaryl.

Unless otherwise stated, the term “heteroatom” or “ring heteroatom” ismeant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P),and silicon (Si).

A “substituent group,” as used herein, means a group selected from thefollowing moieties:

(A) —OH, —NH₂, —SH, —CN, —CF₃, —NO₂, oxo, halogen, unsubstituted alkyl,unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstitutedheterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and

(B) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, andheteroaryl, substituted with at least one substituent selected from:

(i) oxo, —OH, —NH₂, —SH, —CN, —CF₃, —NO₂, halogen, unsubstituted alkyl,unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstitutedheterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and

(ii) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, andheteroaryl, substituted with at least one substituent selected from:

(a) oxo, —OH, —NH₂, —SH, —CN, —CF₃, —NO₂, halogen, unsubstituted alkyl,unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstitutedheterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and

(b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, orheteroaryl, substituted with at least one substituent selected from oxo,—OH, —NH₂, —SH, —CN, —CF₃, —NO₂, halogen, unsubstituted alkyl,unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstitutedheterocycloalkyl, unsubstituted aryl, and unsubstituted heteroaryl.

A “size-limited substituent” or “size-limited substituent group,” asused herein means a group selected from all of the substituentsdescribed above for a “substituent group,” wherein each substituted orunsubstituted alkyl is a substituted or unsubstituted C₁-C₂₀ alkyl, eachsubstituted or unsubstituted heteroalkyl is a substituted orunsubstituted 2 to 20 membered heteroalkyl, each substituted orunsubstituted cycloalkyl is a substituted or unsubstituted C₄-C₈cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is asubstituted or unsubstituted 4 to 8 membered heterocycloalkyl.

A “lower substituent” or “lower substituent group,” as used herein meansa group selected from all of the substituents described above for a“substituent group,” wherein each substituted or unsubstituted alkyl isa substituted or unsubstituted C₁-C₈ alkyl, each substituted orunsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8membered heteroalkyl, each substituted or unsubstituted cycloalkyl is asubstituted or unsubstituted C₅-C₇ cycloalkyl, and each substituted orunsubstituted heterocycloalkyl is a substituted or unsubstituted 5 to 7membered heterocycloalkyl.

Unless otherwise stated, structures depicted herein are also meant toinclude all stereochemical forms of the structure; e.g., the R and Sconfigurations for each asymmetric center as well as cis and transconfigurations. Therefore, single stereochemical isomers as well asenantiomeric and diastereomeric mixtures of the present compounds arewithin the scope of the invention.

The compounds of the present invention may have asymmetric centersand/or geometric isomers. Compounds of the present invention containingan asymmetrically substituted atom may be isolated in optically activeor racemic forms. It is well known in the art how to prepare opticallyactive forms, such as by resolution of materials. All chiral,diastereomeric, racemic forms are within the scope of this invention,unless the specific stereochemistry or isomeric form is specificallyindicated. All possible tautomers and cis and trans isomers, asindividual forms and mixtures thereof are within the scope of thisinvention. Additionally, as used herein the term alkyl includes all thepossible isomeric forms of the alkyl group albeit only a few examplesare set forth. Furthermore, when the cyclic groups such as aryl,heteroaryl, heterocycloalkyl are substituted, they include all thepositional isomers albeit only a few examples are set forth.Furthermore, all polymorphic forms, including amorphous form, andhydrates of a compound disclosed herein are within the scope of thisinvention.

Certain compounds of the present invention possess asymmetric carbonatoms (optical centers) or double bonds; the racemates, diastereomers,tautomers, geometric isomers and individual isomers are encompassedwithin the scope of the present invention, as are enantiomers. Thecompounds of the present invention do not include those which are knownin the art to be too unstable to synthesize and/or isolate.

Unless otherwise stated, structures depicted herein are also meant toinclude compounds which differ only in the presence of one or moreisotopically enriched atoms. For example, compounds having the presentstructures except for the replacement of a hydrogen by a deuterium ortritium, or the replacement of a carbon by ¹³C- or ¹⁴C-enriched carbonare within the scope of this invention.

The compounds of the present invention may also contain unnaturalproportions of atomic isotopes at one or more of atoms that constitutesuch compounds. For example, the compounds may be radiolabeled withradioactive isotopes, such as for example tritium (³H), iodine-125(¹²⁵I) or carbon-14 (¹⁴C). All isotopic variations of the compounds ofthe present invention, whether radioactive or not, are encompassedwithin the scope of the present invention.

The terms “a,” “an,” or “a(n),” when used in reference to a group ofsubstituents herein, mean at least one. For example, where a compound issubstituted with “an” alkyl or aryl, the compound is optionallysubstituted with at least one alkyl and/or at least one aryl.

Unless indicated otherwise, the term “derivative” in the context of acompound disclosed herein refers to a compound afforded by chemicalmodification, e.g., by the bonding of one or more substituent groups asdescribed herein.

Where a moiety is substituted with an R substituent, the group may bereferred to as “R-substituted.” Where a moiety is R-substituted, themoiety is substituted with at least one R substituent and each Rsubstituent is optionally different. For example, where a moiety hereinis R^(1A)-substituted or unsubstituted alkyl, a plurality of R^(1A)substituents may be attached to the alkyl moiety wherein each R^(1A)substituent is optionally different. Where an R-substituted moiety issubstituted with a plurality R substituents, each of the R-substituentsmay be differentiated herein using a prime symbol (′) such as R′, R″,etc. For example, where a moiety is R^(1A)-substituted or unsubstitutedalkyl, and the moiety is substituted with a plurality of R^(1A)substituents, the plurality of R^(1A) substitutents may bedifferentiated as R^(1A)′, R^(1A)″, R^(1A)′″, etc. In some embodiments,the plurality of R substituents is 3. In some embodiments, the pluralityof R substituents is 2.

Description of compounds of the present invention are limited byprinciples of chemical bonding known to those skilled in the art.Accordingly, where a group may be substituted by one or more of a numberof substituents, such substitutions are selected so as to comply withprinciples of chemical bonding and to give compounds which are notinherently unstable and/or would be known to one of ordinary skill inthe art as likely to be unstable under ambient conditions, such asaqueous, neutral, and several known physiological conditions. Forexample, a heterocycloalkyl or heteroaryl is attached to the remainderof the molecule via a ring heteroatom in compliance with principles ofchemical bonding known to those skilled in the art thereby avoidinginherently unstable compounds.

The term “pharmaceutically acceptable salts” is meant to include saltsof the active compounds which are prepared with relatively nontoxicacids or bases, depending on the particular substituents found on thecompounds described herein. When compounds of the present inventioncontain relatively acidic functionalities, base addition salts can beobtained by contacting the neutral form of such compounds with asufficient amount of the desired base, either neat or in a suitableinert solvent. Examples of pharmaceutically acceptable base additionsalts include sodium, potassium, calcium, ammonium, organic amino, ormagnesium salt, or a similar salt. When compounds of the presentinvention contain relatively basic functionalities, acid addition saltscan be obtained by contacting the neutral form of such compounds with asufficient amount of the desired acid, either neat or in a suitableinert solvent. Examples of pharmaceutically acceptable acid additionsalts include those derived from inorganic acids like hydrochloric,hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric,monohydrogenphosphoric, dihydrogenphosphoric, sulfuric,monohydrogensulfuric, hydriodic, or phosphorous acids and the like, aswell as the salts derived from relatively nontoxic organic acids likeacetic, propionic, isobutyric, maleic, malonic, benzoic, succinic,suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic,p-tolylsulfonic, citric, tartaric, oxalic, methanesulfonic, and thelike. Also included are salts of amino acids such as arginate and thelike, and salts of organic acids like glucuronic or galactunoric acidsand the like. See e.g., Berge et al., “Pharmaceutical Salts”, Journal ofPharmaceutical Science, 1977, 66, 1-19). Additional information onsuitable pharmaceutically acceptable salts can be found in REMINGTON'SPHARMACEUTICAL SCIENCES, 17th ed., Mack Publishing Company, Easton, Pa.,1985, which is incorporated herein by reference. Certain specificcompounds of the present invention contain both basic and acidicfunctionalities that allow the compounds to be converted into eitherbase or acid addition salts.

Thus, the compounds disclosed herein may exist as salts. Examples ofsuch salts include hydrochlorides, hydrobromides, sulfates,methanesulfonates, nitrates, maleates, acetates, citrates, fumarates,tartrates (e.g., (+)-tartrates, (−)-tartrates or mixtures thereofincluding racemic mixtures), succinates, benzoates and salts with aminoacids such as glutamic acid. These salts may be prepared by methodsknown to those skilled in the art.

The neutral forms of the compounds are preferably regenerated bycontacting the salt with a base or acid and isolating the parentcompound in the conventional manner. The parent form of the compounddiffers from the various salt forms in certain physical properties, suchas solubility in polar solvents.

The term “prodrug” is used according to its plain ordinary meaning andis intended to mean compounds that require a chemical or enzymatictransformation in order to release the active parent drug in vivo priorto producing a pharmacological effect.

A “pharmaceutically acceptable carrier” or “pharmaceutically acceptableexcipient” means a carrier or an excipient that is useful in preparing apharmaceutical composition that is generally safe, non-toxic and neitherbiologically nor otherwise undesirable, and includes a carrier or anexcipient that is acceptable for veterinary use as well as humanpharmaceutical use. “A pharmaceutically acceptable carrier/excipient” asused in the specification and claims includes both one and more than onesuch excipient.

The terms “treating” or “treatment” refers to any indicia of success inthe treatment or amelioration of an injury, pathology or condition,including any objective or subjective parameter such as abatement;remission; diminishing of symptoms or making the injury, pathology orcondition more tolerable to the patient; slowing in the rate ofdegeneration or decline; making the final point of degeneration lessdebilitating; improving a patient's physical or mental well-being. Thetreatment or amelioration of symptoms can be based on objective orsubjective parameters; including the results of a physical examination,neuropsychiatric exams, and/or a psychiatric evaluation. For example,the certain methods presented herein successfully treat cancer bydecreasing the incidence of cancer, in inhibiting its growth and orcausing remission of cancer.

An “effective amount” of a compound is an amount sufficient tocontribute to the treatment, prevention, or reduction of a symptom orsymptoms of a disease. Where recited in reference to a diseasetreatment, an “effective amount” may also be referred to as a“therapeutically effective amount.” A “reduction” of a symptom orsymptoms (and grammatical equivalents of this phrase) means decreasingof the severity or frequency of the symptom(s), or elimination of thesymptom(s). A “prophylactically effective amount” of a drug is an amountof a drug that, when administered to a subject, will have the intendedprophylactic effect, e.g., preventing or delaying the onset (orreoccurrence) a disease, disorder or condition, or reducing thelikelihood of the onset (or reoccurrence) of a disease, disorder orcondition or symptoms thereof. The full prophylactic effect does notnecessarily occur by administration of one dose, and may occur onlyafter administration of a series of doses. Thus, a prophylacticallyeffective amount may be administered in one or more administrations.

The term “topical” in the context of methods described herein relates inthe customary sense to the administration of a compound orpharmaceutical composition which is incorporated into a suitablepharmaceutical carrier and administered at a topical treatment site of asubject. Accordingly, the term “topical pharmaceutical composition”includes those pharmaceutical forms in which the compound isadministered externally by direct contact with a topical treatment site,e.g., the eye or the skin. The term “topical ocular pharmaceuticalcomposition” refers to a pharmaceutical composition suitable foradministering directly to the eye. The term “topical epidermalpharmaceutical composition” refers to a pharmaceutical compositionsuitable for administering directed to the epidermal layer of the skin,e.g., the palpebra, the supercilium, the scalp, or the body. The term“topical administering” refers to administering externally by directcontact with a topical treatment site. The term “topical epidermaladministering” refers to administering externally by direct contact withthe epidermis. The term “topical ocular administering” refers toadministering externally by direct contact with the eye.

II. Compositions

In one aspect, a compound having the formula

or pharmaceutically acceptable salt thereof is provided. In formula (I)R¹ is substituted or unsubstituted aryl or substituted or unsubstitutedheteroaryl. L¹ is a bond, substituted or unsubstituted C₁-C₁₀ alkyleneor substituted or unsubstituted 2 to 10 membered heteroalkylene. L² is abond, substituted or unsubstituted C₁-C₁₀ alkylene, substituted orunsubstituted arylene or substituted or unsubstituted heteroarylene. L³is a bond or substituted or unsubstituted C₁-C₁₀ alkylene. R² issubstituted or unsubstituted alkyl, substituted or unsubstitutedheteroalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl.

L¹ may be a bond, substituted or unsubstituted C₁-C₁₀ (e.g. C₂-C₆)alkylene, or substituted or unsubstituted 2 to 10 membered (e.g. 2 to 6membered) heteroalkylene. In one embodiment, L¹ is substituted orunsubstituted C₁-C₁₀ alkylene. In one embodiment, L¹ is substituted orunsubstituted C₂-C₆ alkylene. In one embodiment, L¹ is unsubstitutedC₂-C₆ alkylene. In one embodiment, L¹ is unsubstituted propylene. In oneembodiment, L¹ is a bond.

L¹ may be linear or branched substituted or unsubstituted C₁-C₆alkylene. In one embodiment, L¹ is linear substituted or unsubstitutedC₁-C₆ (e.g. C₂-C₅) alkylene. In one embodiment, L¹ is branchedsubstituted or unsubstituted C₁-C₆ alkylene. In one embodiment, L¹ isunsubstituted C₁-C₆ alkylene. In one embodiment, L¹ is unsubstitutedC₂-C₆ alkylene. In one embodiment, L¹ is substituted or unsubstitutedpropylene. In one embodiment, L¹ is unsubstituted propylene. L¹ may besaturated substituted or unsubstituted C₁-C₁₀ (e.g. C₂-C₆) alkylene. A“saturated alkylene,” as used herein, refers to an alkylene consistingonly of hydrogen and carbon atoms that are bonded exclusively by singlebonds. Thus, in one embodiment, L¹ is unsubstituted saturated C₂-C₆alkylene. In one embodiment, L¹ is substituted or unsubstituted 2 to 6membered heteroalkylene. L¹ may be linear or branched substituted orunsubstituted 2 to 6 membered heteroalkylene. In one embodiment, L¹ islinear substituted or unsubstituted 2 to 6 membered heteroalkylene. Inone embodiment, L¹ is branched substituted or unsubstituted 2 to 6membered heteroalkylene. L¹ may be saturated substituted orunsubstituted 2 to 10 membered (e.g. 2 to 6 membered) heteroalkylene. A“saturated heteroalkylene,” as used herein, refers to a heteroalkyleneconsisting of hydrogen atoms, carbon atoms and heteroatoms (e.g. S, N,O) that are bonded exclusively by single bonds. Thus, in one embodiment,L¹ is unsubstituted saturated 2 to 6 membered heteroalkylene.

L¹ may be substituted or unsubstituted alkylene or substituted orunsubstituted heteroalkylene. In one embodiment, L¹ isR^(L1)-substituted or unsubstituted C₁-C₁₀ (e.g. C₂-C₆) alkylene orR^(L1)-substituted or unsubstituted 2 to 10 membered (e.g. 2 to 6membered) heteroalkylene, wherein R^(L1) at each occurrence isindependently hydroxyl or halogen (e.g. chloro, fluoro). In a furtherembodiment, R^(L1) is hydroxyl. In still a further embodiment, R^(L1) isfluoro.

In one embodiment, L¹ is R^(L1)-substituted or unsubstituted C₂-C₆alkylene. In a further embodiment, R^(L1) is hydroxyl. In yet a furtherembodiment, R^(L1) is fluoro. In a further embodiment, R^(L1) is chloro.In one embodiment, L¹ is substituted or unsubstituted C₁-C₆ alkylene. Inone embodiment, L¹ is unsubstituted C₁-C₆ alkylene. In one embodiment,L¹ is unsubstituted C₁, C₂, C₃, C₄, C₅, or C₆ alkylene. In oneembodiment, L¹ is substituted or unsubstituted propylene.

In one embodiment, L¹ is R^(L1)-substituted or unsubstituted C₂-C₆alkylene, wherein R^(L1) is hydroxyl or halogen. Where L¹ isR^(L1)-substituted alkylene or R^(L1)-substituted heteroalkylene, L¹ maybe substituted with at least one R^(L1)-substituent and eachR^(L1)-substituent may be optionally different. For example, where L¹ isR^(L1)-substituted or unsubstituted alkylene in the context of formula(I), a single R^(L1) substituent may be attached to the L¹ alkylene or aplurality of R^(L1) substituents may be attached to the L¹ alkylene andeach R^(L1) substituent may be optionally different (e.g. hydroxyl orhalogen).

For the compounds provided herein including embodiments thereof, L² maybe substituted or unsubstituted arylene, substituted or unsubstitutedheteroarylene or substituted or unsubstituted alkylene. In oneembodiment, L² is substituted or unsubstituted C₅-C₁₀ (e.g. C₅) arylene,substituted or unsubstituted 5 to 10 membered (e.g. 5 to 6 membered)heteroarylene or substituted or unsubstituted C₁-C₁₀ (e.g. C₂-C₆)alkylene. L² may be unsubstituted C₅-C₁₀ (e.g. C₅) arylene,unsubstituted 5 to 10 membered (e.g. 5 to 6 membered) heteroarylene orunsubstituted C₁-C₁₀ (e.g. C₂-C₆) alkylene. Thus, in one embodiment, L²is unsubstituted arylene, unsubstituted heteroarylene or unsubstitutedalkylene. In some further embodiment, L² is unsubstituted heteroarylene.In some other further embodiment, L² is pyridinylene, thiophenylene,pyridylene or furanylene. In yet another further embodiment, L² isthiophene-2,5-diyl. In another further embodiment, L² ispropylene-1,3-diyl. The terms “pyridinylene,” “thiophenylene,”“pyrrolylene” and “furanylene” refer, as customary in the art, todivalent forms of pyridine, thiophene, pyrrole, and furan, respectively.

In one embodiment, L² is R^(L2)-substituted or unsubstituted arylene,R^(L2)-substituted or unsubstituted heteroarylene or R^(L2)-substitutedor unsubstituted C₁-C₁₀ (e.g. C₂-C₆) alkylene, wherein R^(L2) ishydroxyl or halogen. In a further embodiment, L² is R^(L2)-substitutedor unsubstituted heteroarylene. In one embodiment, L² isR^(L2)-substituted arylene (e.g. C₅-C₁₀ arylene). In one embodiment, L²is R^(L2)-substituted heteroarylene (e.g. 5 to 6 memberedheteroarylene). In one embodiment, L² is R^(L2)-substituted alkylene(e.g. C₁-C₁₀ alkylene). Where L² is R^(L2)-substituted arylene,R^(L2)-substituted heteroarylene, or R^(L2)-substituted alkylene, L² maybe substituted with at least one R^(L2)-substituent and eachR^(L2)-substituent may be optionally different. For example, where L² isR^(L2)-substituted or unsubstituted alkylene, a single R^(L2)substituent may be attached to the L² alkylene or a plurality of R^(L2)substituents may be attached to the L² alkylene and each R^(L2)substituent may be optionally different (e.g. hydroxyl or halogen).

For the compounds provided herein including embodiments thereof, R² maybe substituted or unsubstituted alkyl, substituted or unsubstitutedheteroalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted heterocycloalkyl, substituted or unsubstituted aryl, orsubstituted or unsubstituted heteroaryl. In one embodiment, R² issubstituted or unsubstituted C₁-C₁₀ alkyl, or substituted orunsubstituted 2 to 10 membered heteroalkyl. In one embodiment, R² issubstituted or unsubstituted C₁-C₁₀ alkyl. In one embodiment, R² issubstituted or unsubstituted 2 to 10 membered heteroalkyl, whereinR^(2A) at each occurrence is independently halogen, hydroxyl,R^(2B)-substituted or unsubstituted alkyl, R^(2B)-substituted orunsubstituted heteroalkyl, R^(2B)-substituted or unsubstitutedcycloalkyl, R^(2B)-substituted or unsubstituted heterocycloalkyl,R^(2B)-substituted or unsubstituted aryl or R^(2B)-substituted orunsubstituted heteroaryl; R^(2B) at each occurrence is independentlyhalogen, hydroxyl, R^(2C)-substituted or unsubstituted alkyl,R^(2C)-substituted or unsubstituted heteroalkyl, R^(2C)-substituted orunsubstituted cycloalkyl, R^(2C)-substituted or unsubstitutedheterocycloalkyl, R^(2C)-substituted or unsubstituted aryl, orR^(2C)-substituted or unsubstituted heteroaryl; R^(2C) at eachoccurrence is independently halogen, hydroxyl, unsubstituted alkyl,unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstitutedheterocycloalkyl, unsubstituted aryl or unsubstituted heteroaryl.

In one embodiment, R² is R^(2A)-substituted or unsubstituted C₁-C₁₀alkyl, or R^(2A)-substituted or unsubstituted 2 to 10 memberedheteroalkyl. R^(2A) at each occurrence is independently halogen,hydroxyl, R^(2B)-substituted or unsubstituted alkyl, R^(2B)-substitutedor unsubstituted heteroalkyl, R^(2B)-substituted or unsubstitutedcycloalkyl, R^(2B)-substituted or unsubstituted heterocycloalkyl,R^(2B)-substituted or unsubstituted aryl or R^(2B)-substituted orunsubstituted heteroaryl. R^(2B) at each occurrence is independentlyhalogen, hydroxyl, R^(2C)-substituted or unsubstituted alkyl,R^(2C)-substituted or unsubstituted heteroalkyl, R^(2C)-substituted orunsubstituted cycloalkyl, R^(2C)-substituted or unsubstitutedheterocycloalkyl, R^(2C)-substituted or unsubstituted aryl, orR^(2C)-substituted or unsubstituted heteroaryl. R^(2C) at eachoccurrence is independently halogen, hydroxyl, unsubstituted alkyl,unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstitutedheterocycloalkyl, unsubstituted aryl or unsubstituted heteroaryl.

In one embodiment, R² is R^(2A)-substituted or unsubstituted C₁-C₁₀alkyl. In one embodiment, R² is R^(2A)-substituted or unsubstituted 2 to10 membered heteroalkyl.

In one embodiment, R^(2A) is R^(2B)-substituted or unsubstituted alkylor R^(2B)-substituted or unsubstituted heteroalkyl. In one embodiment,R^(2A) is R^(2B)-substituted or unsubstituted alkyl. In one embodiment,R^(2A) is R^(2B)-substituted or unsubstituted heteroalkyl.

In one embodiment, R^(2A) is halogen or hydroxyl. In one embodiment,R^(2A) is halogen. In one embodiment, R^(2A) is hydroxyl.

In one embodiment, R² is substituted with a single substituent R^(2A) ora plurality of substituents R^(2A), wherein R^(2A) at each occurrence isindependently selected. In one embodiment, R^(2A) at each occurrence ishalogen. In one embodiment, R^(2A) at each occurrence is hydroxyl.

R² is R^(2A)-substituted or unsubstituted C₁-C₁₀ (e.g. C₂-C₈) alkyl andR^(2A) is hydroxyl. Thus, in one embodiment, R² is R^(2A)-substituted orunsubstituted C₁-C₁₀ alkyl and R^(2A) is hydroxyl. In one embodiment, R²is R^(2A)-substituted or unsubstituted C₃-C₆ alkyl and R^(2A) ishydroxyl. Where R² is R^(2A)-substituted C₁-C₁₀ (e.g. C₂-C₈) alkyl andR^(2A) is hydroxyl, R² is substituted with at least one (e.g. one, two,three, four, five or six) R^(2A)-substitutent. For example, R² may beR^(2A)-substituted C₃ alkyl, wherein R^(2A) is a first hydroxyl and asecond hydroxyl, wherein the first hydroxyl is attached to C₂ (carbonnumber 2) of the C₃ alkyl and the second hydroxyl is attached to C₃(carbon number 3) of the C₃ alkyl. In one embodiment, R² isR^(2A)-substituted C₄ alkyl, R^(2A) is a first hydroxyl, a secondhydroxyl and a third hydroxyl, wherein the first hydroxyl is attached toC₂ of the C₄ alkyl, the second hydroxyl is attached to C₃ of the C₄alkyl and the third hydroxyl is attached to C₄ of the C₄ alkyl. In oneembodiment, R² is R^(2A)-substituted C₅ alkyl, R^(2A) is a firsthydroxyl, a second hydroxyl, a third hydroxyl and a fourth hydroxyl,wherein the first hydroxyl is attached to C₂ of the C₅ alkyl, the secondhydroxyl is attached to C₃ of the C₅ alkyl, the third hydroxyl isattached to C₄ of the C₅ alkyl and the fourth hydroxyl is attached to C₅of the C₅ alkyl. In one embodiment, R² is R^(2A)-substituted C₆ alkyl,R^(2A) is a first hydroxyl, a second hydroxyl, a third hydroxyl, afourth hydroxyl and a fifth hydroxyl, wherein the first hydroxyl isattached to C₂ of the C₆ alkyl, the second hydroxyl is attached to C₃ ofthe C₆ alkyl, the third hydroxyl is attached to C₄ of the C₆ alkyl, thefourth hydroxyl is attached to C₅ of the C₆ alkyl and the fifth hydroxylis attached to C₆ of the C₆ alkyl. A hydroxyl which is referred toherein as being attached to C₃ of the R^(2A)-substituted (e.g. C₅)alkyl, is a hydroxyl bonded to the carbon at position 3 of theR^(2A)-substituted alkyl. In the context of the compound of formula (I),carbon 3 of R^(2A)-substituted alkyl is the carbon separated by threebonds from the oxygen forming a bond with the carbonyl group of thecompound. In the context of formula (I) the oxygen bonded to thecarbonyl group is indicated by an asterisk in the below structure:

For the compound provided herein including embodiments thereof, L³ maybe substituted or unsubstituted C₁-C₆ (e.g. C₂-C₅) alkylene. In oneembodiment, L³ is unsubstituted C₁, C₂, C₃, C₄, C₅, or C₆ alkylene. Inone embodiment, L³ is unsubstituted C₁-C₆ (e.g. C₂-C₅) alkylene. In oneembodiment, L³ is unsubstituted C₂-C₅ (e.g. C₃-C₅) alkylene. In oneembodiment, L³ is unsubstituted ethylene.

For the compound provided herein including embodiments thereof. R¹ maybe R^(1A)-substituted or unsubstituted aryl or R^(1A)-substituted orunsubstituted heteroaryl and R^(1A) is halogen, unsubstituted C₁-C₆alkyl, —CF₃, —OCF₃, or —OR^(1B), and R^(1B) is unsubstituted C₁-C₆alkyl. In one embodiment, R¹ is R^(1A)-substituted or unsubstituted aryl(e.g. C₅-C₁₀ aryl) or R^(1A)-substituted or unsubstituted heteroaryl(e.g. 5 to 10 membered heteroaryl), wherein R^(1A) is halogen (e.g.fluor or chloro), unsubstituted C₁-C₆ (e.g. C₂-C₅) alkyl, —CF₃, —OCF₃,or —OR^(1B), wherein R^(1B) is unsubstituted C₁-C₆ (e.g. C₂-C₅) alkyl.In one embodiment, R¹ is R^(1A)-substituted (e.g. C₅-C₁₀) aryl orR^(1A)-substituted (e.g. 5 to 10 membered) heteroaryl, wherein R^(1A) ishalogen, unsubstituted C₁-C₆ (e.g. C₂-C₅) alkyl, —CF₃, —OCF₃, or—OR^(L13), wherein R^(L13) is unsubstituted C₁-C₆ (e.g. C₂-C₅) alkyl.Where R¹ is R^(1A)-substituted aryl (e.g. C₅-C₁₀ aryl) orR^(1A)-substituted (e.g. 5 to 10 membered heteroaryl), R¹ may besubstituted with at least one R^(1A)-substitutent and eachR^(1A)-substitutent may be optionally different (e.g. halogen,unsubstituted C₁-C₆ alkyl, CF₃, —OCF₃, or —OR^(1B)). For example, whereR¹ is R^(1A)-substituted aryl, a single R^(1A) substituent may beattached to the R¹ aryl or a plurality of R^(1A) substituents may beattached to the R¹ aryl and each R^(1A) substituent may be optionallydifferent (e.g. halogen, unsubstituted C₁-C₆ alkyl, CF₃, —OCF₃, or—OR^(1B)). In one embodiment, R¹ is R^(1A)-substituted 5 to 10 memberedheteroaryl, wherein R^(1A) is halogen, unsubstituted C₂-C₅ alkyl, —CF₃,—OCF₃, or —OR^(L13), wherein R^(1B) is unsubstituted C₁-C₆ (e.g. C₂-C₅)alkyl. In one embodiment, R¹ is R^(1A)-substituted C₅-C₁₀ aryl, whereinR^(1A) is halogen, unsubstituted C₂-C₅ alkyl, —CF₃, —OCF₃, or —OR^(1B),wherein R^(1B) is unsubstituted C₁-C₆ (e.g. C₂-C₅) alkyl. In oneembodiment, R¹ is R^(1A)-substituted phenyl, wherein R^(1A) is halogen,unsubstituted C₂-C₅ alkyl, —CF₃, —OCF₃, or —OR^(1B), wherein R^(1B) isunsubstituted C₁-C₆ (e.g. C₂-C₅) alkyl. In one embodiment, R¹ isR^(1A)-substituted phenyl, wherein R^(1A) is halogen. In one embodiment,R¹ is R^(1A)-substituted phenyl, wherein R^(1A) is chloro. In oneembodiment, R¹ has the formula:

wherein R^(1A)′ and R^(1A)″ are independently halogen, unsubstitutedC₁-C₆ alkyl, —CF₃, —OCF₃, or —OR^(1B), wherein R^(1B) is unsubstitutedC₁-C₆ alkyl.

In one embodiment, the compound has the structure of formula:

Where the compound has the structure of formula (III), n is 1 to 10, andR^(2D) at each occurrence is independently hydrogen or hydroxyl. Informula (III) n may be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In oneembodiment, 1, 2, 3, 4, 5 or 6 R^(2D) substituents are not hydrogen. Inone embodiment, 2 R^(2D) substituents are not hydrogen. In oneembodiment, 3 R^(2D) substituents are not hydrogen. In one embodiment, 4R^(2D) substituents are not hydrogen. In one embodiment, 5 R^(2D)substituents are not hydrogen. In one embodiment, 6 R^(2D) substituentsare not hydrogen. In one embodiment, 1 R^(2D) substituent is hydroxyl.In one embodiment, 2 R^(2D) substituents are hydroxyl. In oneembodiment, 3 R^(2D) substituents are hydroxyl. In one embodiment, 4R^(2D) substituents are hydroxyl. In one embodiment, n is greater than1, e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10. In one embodiment, n is 3 and 2R^(2D) substituents are hydroxyl. In one embodiment, n is 4 and 3 R^(2D)substituents are hydroxyl. In one embodiment, n is 5 and 4 R^(2D)substituents are hydroxyl. In one embodiment, R² is not hydroxyethyl.

In one embodiment, the compound has the structure of formula:

In one embodiment, the compound has the structure of formula:

In one embodiment, the compound has the structure of formula:

In one embodiment, the compound has the structure of formula:

In one embodiment, the compound has the structure of formula:

In one embodiment, the compound has the structure of formula:

In one embodiment, the compound has the structure of formula:

In one embodiment, the compound has the structure of formula:

In one embodiment, the compound has the structure of formula:

The compound described herein including embodiments thereof (e.g., acompound with structure of any one of formulae (I), (III), (IV), (V),(VI), (VII), or derivative, isomer or enantiomer thereof) can beprovided, where applicable, as a pharmaceutically acceptable salt asdefined herein, where the compound admits to formation of apharmaceutically acceptable salt. In one embodiment, a pharmaceuticallyacceptable salt of a compound with structure of any one of formulae (I),(III), (IV), (V), (VI), (VII), or isomer or enantiomer thereof, isprovided herein, wherein the compound admits to formation of apharmaceutically acceptable salt.

III. Pharmaceutical Compositions

In another aspect, an ophthalmic pharmaceutical composition including acompound provided herein and embodiments thereof (e.g., a compound offormula (I), (III), (IV), (V), (VI), (VII), or derivative, isomer orenantiomer thereof) is provided. In one embodiment, the compound has thestructure of formula (I). In one embodiment, the compound has thestructure of formula (III). In one embodiment, the compound has thestructure of formula (IV). In one embodiment, the compound has thestructure of one of formulae (IVa)-(IVb). In one embodiment, thecompound has the structure of formula (V). In one embodiment, thecompound has the structure of one of formulae (Va)-(Vd). In oneembodiment, the compound has the structure of formula (VI). In oneembodiment, the compound has the structure of one of formulae(VIa)-(VIh). In one embodiment, the compound has the structure offormula (VII). In one embodiment, the compound has the structure of oneof formulae (VIIa)-(VIIp).

In one embodiment, the pharmaceutical composition is a solution,emulsion, gel or foam. In one embodiment, the pharmaceutical compositionis a solution. In one embodiment, the pharmaceutical composition is anemulsion. In one embodiment, the pharmaceutical composition is a gel. Inone embodiment, the pharmaceutical composition is a foam.

A. Formulations

The compounds and pharmaceutical compositions disclosed herein can beprepared and administered in a variety of forms including solution,emulsion, gel or foam. Accordingly, pharmaceutical compositionscontemplated herein include a pharmaceutically acceptable carrier orexcipient and one or more compounds described herein. “Solution” refersin the customary sense to a liquid pharmaceutical composition in which acompound (e.g., a compound described herein), is at least partiallydissolved, preferably fully dissolved, and which can be administered asa liquid. “Emulsion” refers in the customary sense to a mixture of twoor more immiscible liquids, one compound (e.g., a compound describedherein or solution thereof) being dispersed through the other compound(e.g., a carrier as described herein). “Gel” refers in the customarysense to a highly viscous solution, emulsion, or colloidal suspension ofa compound within a continuous fluid phase resulting in a viscoussemirigid fluid. “Colloid” refers in the customary sense to acomposition which includes a continuous medium throughout which aredistributed small particles which do not settle under the influence ofgravity. “Foam” refers in the customary sense to a composition whichincludes a continuous medium (i.e., solution, emulsion, gel and thelike) through which gas (e.g., air) is dispersed.

Pharmaceutical compositions contemplated herein may be prepared bycombining a therapeutically effective amount of at least one compound asdescribed herein as an active ingredient in combination with one or moreconventional pharmaceutically acceptable excipients, and by preparationof unit dosage forms suitable for topical use. The therapeuticallyefficient amount typically is between about 0.0001 and about 5% (w/v),preferably about 0.001 to about 1.0% (w/v) in liquid formulations whichinclude solutions, emulsions, gels and foams. Pharmaceutical admixturessuitable for use in the present invention include those described, forexample, in PHARMACEUTICAL SCIENCES (17th Ed., Mack Pub. Co., Easton,Pa.) and WO 96/05309, the teachings of both of which are herebyincorporated by reference.

The pharmaceutical preparation is preferably in unit dosage form. Insuch form the preparation is subdivided into unit doses containingappropriate quantities of the active component. The unit dosage form canbe a packaged preparation, the package containing discrete quantities ofpreparation, such as packeted tablets, capsules, and powders in vials orampoules. Also, the unit dosage form can be a capsule, tablet, cachet,or lozenge itself, or it can be the appropriate number of any of thesein packaged form.

Some compounds may have limited solubility in water and therefore mayrequire a surfactant or other appropriate co-solvent in the composition.Such co-solvents include: Polysorbate 20, 60, and 80; Pluronic F-68,F-84, and P-103; cyclodextrin; and polyoxyl 35 castor oil. Suchco-solvents are typically employed at a level between about 0.01% andabout 2% by weight.

Viscosity greater than that of simple aqueous solutions may be desirableto decrease variability in dispensing the formulations, to decreasephysical separation of components of a suspension or emulsion offormulation, and/or otherwise to improve the formulation. Such viscositybuilding agents include, for example, polyvinyl alcohol, polyvinylpyrrolidone, methyl cellulose, hydroxy propyl methylcellulose,hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propylcellulose, chondroitin sulfate and salts thereof, hyaluronic acid andsalts thereof, and combinations of the foregoing. Such agents aretypically employed at a level between about 0.01% and about 2% byweight.

The compositions of the present invention may additionally includecomponents to provide sustained release and/or comfort. Such componentsinclude high molecular weight, anionic mucomimetic polymers, gellingpolysaccharides, and finely-divided drug carrier substrates. Thesecomponents are discussed in greater detail in U.S. Pat. Nos. 4,911,920;5,403,841; 5,212,162; and 4,861,760. The entire contents of thesepatents are incorporated herein by reference in their entirety for allpurposes. US Patent application publication No. US 2011-0124736 A1, alsocorresponding to U.S. patent application Ser. No. 12/940,711, is herebyincorporated by reference in its entirety.

For ophthalmic application, preferably solutions are prepared using aphysiological saline solution as a major vehicle. The pH of suchophthalmic solutions should preferably be maintained between 4.5 and 8.0with an appropriate buffer system, a neutral pH being preferred but notessential. The formulations may also contain conventional,pharmaceutically acceptable preservatives, stabilizers and surfactants.

Various buffers and means for adjusting pH may be used so long as theresulting preparation is ophthalmically acceptable. Accordingly, buffersinclude acetate buffers, citrate buffers, phosphate buffers and boratebuffers. Acids or bases may be used to adjust the pH of theseformulations as needed.

Preferred preservatives that may be used in the pharmaceuticalcompositions of the present invention include, but are not limited to,benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetateand phenylmercuric nitrate. A preferred surfactant is, for example,Tween 80. Likewise, various preferred vehicles may be used in theophthalmic preparations of the present invention. These vehiclesinclude, but are not limited to, polyvinyl alcohol, povidone,hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose,hydroxyethyl cellulose cyclodextrin and purified water.

Tonicity agents may be added as needed or convenient. They include, butare not limited to, salts, particularly sodium chloride, potassiumchloride, mannitol and glycerin, or any other suitable ophthalmicallyacceptable tonicity adjustor.

An ophthalmically acceptable antioxidant for use in the presentinvention includes, but is not limited to, sodium metabisulfite, sodiumthiosulfate, acetylcysteine, butylated hydroxyanisole and butylatedhydroxytoluene.

Other excipient components which may be included in the ophthalmicpreparations are chelating agents. The preferred chelating agent isedentate disodium, although other chelating agents may also be used inplace of or in conjunction with it.

The ophthalmic formulations of the present invention are convenientlypackaged in forms suitable for metered application, such as incontainers equipped with an orifice, to facilitate application to theeye. Vials suitable for unit dose application are usually made ofsuitable inert, non-toxic plastic material, and generally containbetween about 0.5 and about 15 ml solution, emulsion, gel or foam. Onepackage may contain one or more unit doses.

Preservative-free solutions are often formulated in non-resealablecontainers containing up to about ten, preferably up to about five unitsdoses, where a typical unit dose is from one to about 8 drops,preferably one to about 3 drops.

Typically, the compounds are applied repeatedly for a sustained periodof time topically on the part of the body to be treated, for example,the eye. The preferred dosage regimen will generally involve regularadministration for a period of treatment of at least one month, morepreferably at least three months, and most preferably at least sixmonths. The regular administration can be 1, 2, 3, 4 or even more timesper day.

IV. Methods of Treatment

In another aspect, a method of treating an ophthalmic disease in a humanis provided. The method includes administering a therapeuticallyeffective amount of a compound provided herein and embodiments thereof(e.g., a compound of formula (I), (III), (IV), (V), (VI), (VII), orderivative, isomer or enantiomer thereof) to a subject in need thereof.In one embodiment, the administering is topical administering. In oneembodiment, the disease is macular degeneration. In one embodiment, thedisease results from intraocular pressure. In one embodiment, thedisease is glaucoma.

In one embodiment, a combination treatment with a β-blocker (orβ-adrenergic antagonist) including carteolol, levobunolol,metiparanolol, timolol hemihydrate, timolol maleate, α 1-selectiveantagonists such as betaxolol, and the like, or pharmaceuticallyacceptable salts or prodrugs thereof is provided.

In one embodiment, a combination treatment with an adrenergic agonistsincluding non-selective adrenergic agonists such as epinephrine borate,epinephrine hydrochloride, and dipivefrin, and the like, orpharmaceutically acceptable salts or prodrugs thereof, and α 2-selectiveadrenergic agonists such as apraclonidine, brimonidine, and the like, orpharmaceutically acceptable salts or prodrugs thereof is provided.

In one embodiment, a combination treatment with a carbonic anhydraseinhibitors including acetazolamide, dichlorphenamide, methazolamide,brinzolamide, dorzolamide, and the like, or pharmaceutically acceptablesalts or prodrugs thereof is provided.

In one embodiment, a combination treatment with a cholinergic agonistincluding direct acting cholinergic agonists such as carbachol,pilocarpine hydrochloride, pilocarpine nitrate, pilocarpine, and thelike, or pharmaceutically acceptable salts or prodrugs thereof isprovided.

In one embodiment, a combination treatment with a chlolinesteraseinhibitors such as demecarium, echothiophate, physostigmine, and thelike, or pharmaceutically acceptable salts or prodrugs thereof isprovided.

In one embodiment, a combination treatment with a glutamate antagonistsor other neuroprotective agents such as Ca²⁺ channel blockers such asmemantine, amantadine, rimantadine, nitroglycerin, dextrophan,detromethorphan, CGS-19755, dihydropyridines, verapamil, emopamil,benzothiazepines, bepridil, diphenylbutylpiperidines,diphenylpiperazines, HOE 166 and related drugs, fluspirilene, eliprodil,ifenprodil, CP-101,606, tibalosine, 2309BT, and 840S, flunarizine,nicardipine, nifedimpine, nimodipine, barnidipine, verapamil,lidoflazine, prenylamine lactate, amiloride, and the like, orpharmaceutically acceptable salts or prodrugs thereof is provided.

In one embodiment, a combination treatment with a prostamides such asbimatoprost, or pharmaceutically acceptable salts or prodrugs thereof isprovided.

In one embodiment, a combination treatment with a prostaglandinincluding travoprost, UF0-21, chloprostenol, fluprostenol,13,14-dihydro-chloprostenol, isopropyl unoprostone, latanoprost and thelike is provided.

In one embodiment, a combination treatment with a cannabinoid includingCB1 agonists such as WIN-55212-2 and CP-55940 and the like, orpharmaceutically acceptable salts or prodrugs thereof is provided.

In another aspect, a method of reducing corneal thickening is provided.The method includes administering a therapeutically effective amount ofa compound provided herein and embodiments thereof (e.g., a compound offormula (I), (III), (IV), (V), (VI), (VII), or derivative, isomer orenantiomer thereof) to a subject in need thereof. In one embodiment, thesubject suffers from glaucoma. In one embodiment, the subject suffersfrom ocular hypertension.

In one embodiment, a method of using a compound disclosed herein for themanufacture of a medicament for the treatment of glaucoma or ocularhypertension is provided. In one embodiment, the compound has thestructure of any one of formulae (I), (III), (IV), (V), (VI), or (VII).In one embodiment, the compound has the structure of formula (I). In oneembodiment, the compound has the structure of formula (III). In oneembodiment, the compound has the structure of formula (IV). In oneembodiment, the compound has the structure of one of formulae(IVa)-(IVb). In one embodiment, the compound has the structure offormula (V). In one embodiment, the compound has the structure of one offormulae (Va)-(Vd). In one embodiment, the compound has the structure offormula (VI). In one embodiment, the compound has the structure of oneof formulae (VIa)-(VIh). In one embodiment, the compound has thestructure of formula (VII). In one embodiment, the compound has thestrucutre of one of formulae (VIIa)-(VIIp).

V. Examples

Abbreviations used herein have the customary meaning in the chemicalarts. Specific abbreviations include the following: TBDMSO:(tert-butyldimethylsilyl)oxy; DMF: dimethylformamide; EDC:1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride; DMAP:4-dimethylaminopyridine; THF: tetrahydrofuran; Bu₄NF: tetrabutylammoniumfluoride.

Example 1 Synthesis of (R)-2,3-dihydroxypropyl5-(3-((1R,2R,3R,5R)-5-chloro-2-(3,5-dichlorophenethyl)-3-hydroxycyclopentyl)propyl)thiophene-2-carboxylate(compound 3)

An exemplary synthesis of compound 3 is provided in scheme 1 following.

((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl5-(3-((1R,2R,3R,5R)-5-chloro-2-(3,5-dichlorophenethyl)-3-hydroxycyclopentyl)propyl)thiophene-2-carboxylate(compound 2)

(R)-(−)-2,2-Dimethyl-1,3-dioxolane-4-methanol (572.2 mg, 4.33 mmol) wasadded to a solution of the carboxylic acid of compound 1 (200 mg, 0.433mmol), 4-(dimethylamino)pyridine (55.3 mg, 0.453 mmol) andN-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (91.3 mg,0.476 mmol) in DMF (3.0 mL) at 23° C. After stirring for 16 hours thereaction solution was diluted with EtOAc and washed with 1N HCl,saturated aqueous NaHCO₃ then brine. The organic portion was dried(MgSO₄), filtered and concentrated in vacuo. Purification of the residueby flash column chromatorgraphy (silica gel, 2:1 hex/EtOAc) afforded211.7 mg (85%) of acetonide protected ester 2 as a clear, viscous oil.The ester 2 (249.0 mg, 0.433 mmol) was stirred at 23° C. in a mixture of1N HCl:THF (1:1, 3.0 mL) for 24 hours. The reaction mixture was thendiluted with EtOAc and washed with water, saturated aqueous NaHCO₃ thenbrine. The organic portion was dried (MgSO₄), filtered and concentratedin vacuo. The residue was purified by flash column chromatography(silica gel, 1:1 hex/EtOAc followed by 100% EtOAc) to give 158.8 mg(68%) of the bishydroxy ester compound 3 as a clear, viscous oil.

Example 2 Synthesis of ((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl5-(3-((1R,2R,3R,5R)-5-chloro-2-(3,5-dichlorophenethyl)-3-hydroxycyclopentyl)propyl)thiophene-2-carboxylate(compound 4)

In accordance with the procedures described for the preparation ofcompound 2 above, use of 100 mg (0.216 mmol) of carboxylic acid ofcompound 1 and 42.8 mg (0.324 mmol) of(S)-(+)-2,2-dimethyl-1,3-dioxolane-4-methanol afforded 72.3 mg (58%) ofacetonide protected ester compound 4.

Example 3 Synthesis of (S)-2,3-dihydroxypropyl5-(3-((1R,2R,3R,5R)-5-chloro-2-(3,5-dichlorophenethyl)-3-hydroxycyclopentyl)propyl)thiophene-2-carboxylate(compound 5)

In accordance with the procedures described for the preparation ofcompound 3 above, use of 72.3 mg (0.125 mmol) of ester 4 provided 43.5mg (65%) of bishydroxy ester compound 5 as a clear, viscous oil.

Example 4 Synthesis of((4R,5R)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl5-(3-((1R,2R,3R,5R)-5-chloro-2-(3,5-dichlorophenethyl)-3-hydroxycyclopentyl)propyl)thiophene-2-carboxylate(compound 6)

In accordance with the procedures described for the preparation ofcompound 2 above, use of 100 mg (0.216 mmol) of carboxylic acid 1 and52.5 mg (0.324 mmol) of(4R,5R)-2,2-dimethyl-1,3-dioxolane-4,5-dimethanol afforded 41.5 mg(31′%) of acetonide protected ester compound 6.

Example 5 Synthesis of (2R,3R)-2,3,4-trihydroxybutyl5-(3-((1R,2R,3R,5R)-5-chloro-2-(3,5-dichlorophenethyl)-3-hydroxycyclopentyl)propyl)thiophene-2-carboxylate(compound 7)

In accordance with the procedures described for the preparation ofcompound 3 above, use of 41.5 mg (0.069 mmol) of ester 6 provided 27.6mg (71%) of trishydroxy ester compound 7 as a clear, viscous oil.

Example 6 Synthesis of((4S,5S)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl5-(3-((1R,2R,3R,5R)-5-chloro-2-(3,5-dichlorophenethyl)-3-hydroxycyclopentyl)propyl)thiophene-2-carboxylate(compound 8)

In accordance with the procedures described for the preparation ofcompound 2 above, use of 100 mg (0.216 mmol) of carboxylic acid 1 and52.5 mg (0.324 mmol) of((4S,5S)-2,2-dimethyl-1,3-dioxolane-4,5-dimethanol afforded 71.9 mg(55%) of acetonide protected ester compound 8.

Example 7 Synthesis of (2S,3S)-2,3,4-trihydroxybutyl5-(3-((1R,2R,3R,5R)-5-chloro-2-(3,5-dichlorophenethyl)-3-hydroxycyclopentyl)propyl)thiophene-2-carboxylate(compound 9)

In accordance with the procedures described for the preparation ofcompound 3 above, use of 71.9 mg (0.118 mmol) of ester 8 provided 39.2mg (59%) of trishydroxy ester compound 9 as a clear, viscous oil.

Example 8 Synthesis of((4R,4′S,5R)-2,2,2′,2′-tetramethyl-[4,4′-bi(1,3-dioxolan)]-5-yl)methyl5-(3-((1R,2R,3R,5R)-5-chloro-2-(3,5-dichlorophenethyl)-3-hydroxycyclopentyl)propyl)thiophene-2-carboxylate(compound 10)

In accordance with the procedures described for the preparation ofcompound 2 above, use of 100 mg (0.216 mmol) of carboxylic acid 1 and60.1 mg (0.259 mmol) of((4S,4′S,5R)-2,2,2′,2′-tetramethyl-[4,4′-bi(1,3-dioxolan)]-5-yl)methanolafforded 79.2 mg (52%) of bisacetonide protected ester compound 10.

Example 9 Synthesis of (2R,3R,4S)-2,3,4,5-tetrahydroxypentyl5-(3-((1R,2R,3R,5R)-5-chloro-2-(3,5-dichlorophenethyl)-3-hydroxycyclopentyl)propyl)thiophene-2-carboxylate(11)

In accordance with the procedures described for the preparation ofcompound 3 above, use of 79.2 mg (0.117 mmol) of ester 10 provided 11.8mg (17%) of ester compound 11 as a clear, viscous oil.

Example 10 Synthesis of(S)-2-hydroxy-2-((4R,4′R,5R)-2,2,2′,2′-tetramethyl-[4,4′-bi(1,3-dioxolan)]-5-yl)ethyl5-(3-((1R,2R,3R,5R)-5-chloro-2-(3,5-dichlorophenethyl)-3-hydroxycyclopentyl)propyl)thiophene-2-carboxylate(compound 12)

In accordance with the procedures described for the preparation ofcompound 2 above, use of 100 mg (0.216 mmol) of carboxylic acid 1 and67.9 mg (0.259 mmol) of(S)-1-((4R,4′R,5R)-2,2,2′,2′-tetramethyl-[4,4′-bi(1,3-dioxolan)]-5-yl)ethane-1,2-diolafforded 90.1 mg (59%) of bisacetonide protected ester compound 12.

Example 11 Synthesis of 2,3,4,5,6-pentahydroxyhexyl5-(3-((1R,2R,3R,5R)-5-chloro-2-(3,5-dichlorophenethyl)-3-hydroxycyclopentyl)propyl)thiophene-2-carboxylate(compound 13)

In accordance with the procedures described for the preparation ofcompound 3 above, use of 65.8 mg (0.093 mmol) of ester 12 provided 43.5mg (75%) of ester 13 as a clear, viscous oil.

VI. Embodiments Embodiment 1

A compound having the formula (I):

or pharmaceutically acceptable salt thereof, wherein, R¹ is substitutedor unsubstituted aryl or substituted or unsubstituted heteroaryl; L¹ isa bond, substituted or unsubstituted C₁-C₁₀ alkylene, or substituted orunsubstituted 2 to 10 membered heteroalkylene; L² is a bond, substitutedor unsubstituted C₁-C₁₀ alkylene, substituted or unsubstituted aryleneor substituted or unsubstituted heteroarylene; L³ is a bond orsubstituted or unsubstituted C₁-C₁₀ alkylene; and R² is substituted orunsubstituted alkyl, substituted or unsubstituted heteroalkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedhetercycloalkyl, substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl.

Embodiment 2

The compound of embodiment 1, wherein R² is R^(2A)-substituted orunsubstituted C₁-C₁₀ alkyl, or R^(2A)-substituted or unsubstituted 2 to10 membered heteroalkyl, wherein R^(2A) at each occurrence isindependently halogen, hydroxyl, R^(2B)-substituted or unsubstitutedalkyl, R^(2B)-substituted or unsubstituted heteroalkyl,R^(2B)-substituted or unsubstituted cycloalkyl, R^(2B)-substituted orunsubstituted heterocycloalkyl, R^(2B)-substituted or unsubstituted arylor R^(2B)-substituted or unsubstituted heteroaryl; R^(2B) at eachoccurrence is independently halogen, hydroxyl, R^(2C)-substituted orunsubstituted alkyl, R^(2C)-substituted or unsubstituted heteroalkyl,R^(2C)-substituted or unsubstituted cycloalkyl, R^(2C)-substituted orunsubstituted heterocycloalkyl, R^(2C)-substituted or unsubstitutedaryl, or R^(2C)-substituted or unsubstituted heteroaryl; R^(2C) at eachoccurrence is independently halogen, hydroxyl, unsubstituted alkyl,unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstitutedheterocycloalkyl, unsubstituted aryl or unsubstituted heteroaryl.

Embodiment 3

The compound of embodiment 3, wherein R² is substituted or unsubstitutedC₁-C₁₀ alkyl.

Embodiment 4

The compound of any one of embodiments 2 or 3, wherein R^(2A) isR^(2B)-substituted or unsubstituted alkyl or R^(2B)-substituted orunsubstituted heteroalkyl.

Embodiment 5

The compound of any one of embodiments 2 to 4, wherein R^(2A) isR^(2B)-substituted or unsubstituted alkyl.

Embodiment 6

The compound of any one of embodiments 2 or 3, wherein R^(2A) is halogenor hydroxyl.

Embodiment 7

The compound of embodiment 1, wherein R^(2A) is hydroxyl.

Embodiment 8

The compound of any one of embodiments 1 to 7, wherein L¹ is substitutedor unsubstituted C₁-C₆ alkylene.

Embodiment 9

The compound of any one of embodiments 1 to 8, wherein L¹ isunsubstituted C₁-C₆ alkylene.

Embodiment 10

The compound of any one of 1 to 9, wherein L¹ is substituted orunsubstituted propylene.

Embodiment 11

The compound of embodiment 1, wherein L¹ is R^(L1)-substituted orunsubstituted C₁-C₁₀ alkylene, or R^(L1)-substituted or unsubstituted 2to 10 membered heteroalkylene, wherein R^(L1) at each occurrence isindependently halogen or hydroxyl.

Embodiment 12

The compound of embodiment 11, wherein R^(L1) is hydroxyl.

Embodiment 13

The compound of embodiment 11, wherein R^(L1) is fluoro.

Embodiment 14

The compound of embodiment 11, wherein L¹ is R^(L1)-substituted orunsubstituted C₁-C₁₀ alkylene.

Embodiment 15

The compound of embodiment 11, wherein R^(L1) is hydroxyl.

Embodiment 16

The compound of embodiment 11, wherein R^(L1) is fluoro.

Embodiment 17

The compound of embodiment 11, wherein L¹ is R^(L1)-substituted orunsubstituted C₂-C₆ alkylene.

Embodiment 18

The compound of embodiment 11, wherein R^(L1) is hydroxyl.

Embodiment 19

The compound of embodiment 11, wherein R^(L1) is fluoro.

Embodiment 20

The compound of embodiment 11, wherein L¹ is unsubstituted C₂-C₆alkylene.

Embodiment 21

The compound of embodiment 1, wherein L¹ is unsubstituted propylene.

Embodiment 22

The compound of any one of embodiments 1 to 9, wherein L² is substitutedor unsubstituted arylene, substituted or unsubstituted heteroarylene orsubstituted or unsubstituted C₁-C₁₀ alkylene.

Embodiment 23

The compound of any one of embodiments 1 to 9, wherein L² isR¹²-substituted or unsubstituted arylene, R¹²-substituted orunsubstituted heteroarylene or R¹²-substituted or unsubstituted C₁-C₁₀alkylene, wherein R¹² is hydroxyl or halogen.

Embodiment 24

The compound of embodiment 1, wherein L² is R¹²-substituted orunsubstituted heteroarylene.

Embodiment 25

The compound of any one of embodiments 1 to 9, wherein L² isunsubstituted arylene, unsubstituted heteroarylene or unsubstitutedalkylene.

Embodiment 26

The compound of embodiment 1, wherein L² is unsubstituted heteroarylene.

Embodiment 27

The compound of embodiment 1, wherein L² is unsubstituted pyridinylene,unsubstituted thiophenylene, unsubstituted pyridylene or unsubstitutedfuranylene.

Embodiment 28

The compound of embodiment 1, wherein L² is thiophene-2,5-diyl.

Embodiment 29

The compound of embodiment 1, wherein L² is propylene-1,3-diyl.

Embodiment 30

The compound of any one of embodiments 1 to 29, wherein R² isR^(2A)-substituted or unsubstituted C₁-C₁₀ alkyl, wherein R^(2A) ishydroxyl.

Embodiment 31

The compound of any one of embodiment 1 to 30, wherein R² isR^(2A)-substituted C₃-C₅ alkyl, wherein R^(2A) is hydroxyl.

Embodiment 32

The compound of any one of embodiments 1 to 31, wherein L³ isunsubstituted C₁-C₆ alkylene.

Embodiment 33

The compound of any one of embodiments 1 to 32, wherein L³ isunsubstituted ethylene.

Embodiment 34

The compound of any one of embodiments 1 to 33, wherein R¹ isR^(1A)-substituted or unsubstituted aryl or R^(1A)-substituted orunsubstituted heteroaryl, wherein R^(1A) is halogen, unsubstituted C₁-C₆alkyl, —CF₃, —OCF₃, or —OR^(1B), wherein R^(1B) is unsubstituted C₁-C₆alkyl.

Embodiment 35

The compound of any one of embodiments 1 to 34, wherein R¹ isR^(1A)-substituted phenyl, wherein R^(1A) is halogen, unsubstitutedC₁-C₆ alkyl, —CF₃, —OCF₃, or —OR^(1B), wherein R^(1B) is unsubstitutedC₁-C₆ alkyl.

Embodiment 36

The compound of any one embodiments 1 to 35, wherein R¹ has the formula:

wherein R^(1A′) and R^(1A″) are independently halogen, unsubstitutedC₁-C₆ alkyl, —CF₃, —OCF₃, or —OR^(1B), wherein R^(1B) is unsubstitutedC₁-C₆ alkyl.

Embodiment 37

The compound of embodiment 1, with structure of formula:

wherein n is 1 to 10; andR^(2D) at each occurrence is independently hydrogen or hydroxyl.

Embodiment 38

An ophthalmic pharmaceutical composition comprising a compound of anyone of embodiments 1 to 37 and a pharmaceutically acceptable carrier.

Embodiment 39

A method of treating an ophthalmic disease in a human, said methodcomprising administering a therapeutically effective amount of acompound of any one of embodiments 1 to 37 a subject in need thereof.

Embodiment 40

The method of embodiment 39, wherein said administering is topicaladministering.

Embodiment 41

The method of embodiment 39, wherein said disease is glaucoma.

Embodiment 42

The method of embodiment 39, wherein said disease is maculardegeneration.

Embodiment 43

The method of embodiment 39, wherein said disease results fromintraocular pressure.

Embodiment 44

A method of reducing corneal thickening, said method comprisingadministering a therapeutically effective amount of a compound of anyone of embodiments 1 to 37 a subject in need thereof.

Embodiment 45

The method of embodiment 44, wherein said subject suffers from glaucoma.

Embodiment 46

The method of embodiment 44, wherein said subject suffers from ocularhypertension.

What is claimed is:
 1. A compound having Formula (III):

wherein: n is 3 to 5; and R^(2D) at each occurrence is independentlyhydrogen or hydroxyl, and wherein 1, 2, 3, 4, or 5 R^(2D) substituentsare not hydrogen.
 2. The compound of claim 1 selected from the groupconsisting of:


3. A method of reducing corneal thickening, said method comprisingadministering a therapeutically effective amount of a compound of claim1 to a subject in need thereof.
 4. The method of claim 3, wherein saidsubject suffers from glaucoma.
 5. The method of claim 3, wherein saidsubject suffers from ocular hypertension.
 6. A pharmaceuticalcomposition comprising the compound according to claim 1 and apharmaceutically acceptable carrier.